The study will look at a non-invasive treatment for people suffering with chronic and episodic headaches. Study subjects will be randomized to an active treatment or an in-active treatment for 2 weeks. After the 2 weeks all subjects will continue to treat with an active treatment for an additional 2 weeks.
The study is a prospective double blind, randomized, sham-controlled, multi-center investigation designed for comparison of two parallel groups, GammaCore® (active treatment) and a sham, (in-active) treatment. The study period begins with a 1-week run-in period, followed by a 2 week comparative period when the subjects are randomized (1:1) to either active treatment or sham (in-active) treatment. The comparative period will be followed by an open label 2 week period, where the subjects in the sham treatment group will switch in treatment assignment and receive an active treatment and the active group will continue to receive an active treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
102
Vagal stimulation
Glostrup Hospital, Danish Headache Centre
Glostrup Municipality, Denmark
Westdeutches Kopfschmerzzentrum
Essen, Germany
Kopfschmerzklinik Königstein
Königstein im Taunus, Germany
Comparison of the Headache Pain Free Attack Rates at 15 Minutes Following the Treatment
Headache pain was collected at the beginning of the attack (all treated attacks) and 15 minutes post treatment pain free attacks. Data was collected in the patient diary.
Time frame: 2 weeks
Change in Disability From Baseline (Randomization) to 2 Weeks After Baseline
Mean difference of scores on a 5 step disability scale. Disability was measured at baseline and after the randomization phase (2 weeks later). Lowest score is 1 and is better than the higher score at 5 that is the worst. An increase, higher scores, means worsening. 1. minor 2. minor/moderate 3. moderate 4. moderate/severe 5. severe
Time frame: 2 weeks
Mean Change of Questionnaire EQ-5D-3L (Euroqol- 5D-3L) From Baseline to After 2 Weeks Treatment
EQ-5D-3L descriptive system comprises 5 dimensions: mobility, self-care, activity, pain and anxiety. Each dimension has 3 levels: 1 = no problems, 2 = moderate problems, 3=extreme problems. Subjects indicate health state by ticking choosing appropriate statement in each dimension and a VAS scale (Overall health) from 0-100 mm where higher score is better (100) than lower score (0). Patients completed the EQ-5D-3L at baseline (the start of the randomized period and at 2 weeks).
Time frame: 2 weeks
Patients Who Used Any Type of Rescue Medication
Following treatment at 15 minutes, patients recorded use of any rescue medication(s) in the diary'
Time frame: 2 weeks
Comparison of the Headache Pain Free Attack Rates at 30 Minutes Following the Treatment
The headache pain was collected at the beginning of the attack and 30 minutes post treatment in the patient diary. The number of pain free (no pain) attacks are compared to all attacks treated
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Klinikum Grosshadern, University of Munich
Munich, Germany
Leiden University Medical Center, Neurology Department, K5-Q-104
Leiden, Netherlands
Hull Royal Infirmary, Neurology Department
Hull, East Yorkshire, United Kingdom
Royal Free, Dept for Neurology and Clinical Neurosciences
London, Greater London, United Kingdom
The Southern Hospital, Neurology Department
Glasgow, Lanarkshire, United Kingdom
The Walton Center, Neurology Department
Liverpool, Merseyside, United Kingdom
Time frame: 2 weeks